Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy
Experimental and Clinical Endocrinology & Diabetes · 2023-04 · 131 (04) · 236-241
DOI: 10.1055/a-2021-0596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, online erschienen am 03.03.2023. Verfasst von Selwan Khamisi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Uppsala University Hospital, Uppsala, Sweden. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uppsala Universitet.
Abstract (Originalsprache)
Objectives
TSH-receptor antibodies (TRAb) targeting the TSH receptor (TSH-R) induce hyperthyroidism in Graves´ disease (GD). Graves´ orbitopathy (GO) is influenced by stimulation of the TSH-R in the orbita. GO has been, among other factors, linked to high TRAb levels. Thyroid stimulating immunoglobulins (TSI) is a relatively new method for assessing TSH-receptor antibodies. The aim of this study was to investigate the role of TSI in the management of GO.
Methods
Patients with newly diagnosed GD (n=30, median age 55 years (range 35–72), 29 women) received pharmacological therapy (methimazole+++thyroxine) for up to 24 months. GO was identified by clinical signs and symptoms. Eleven patients had GO at diagnosis, and another six developed GO during treatment. Blood samples for TSI and other thyroidal biomarkers were obtained at baseline and on five occasions during the 24-month follow-up. Twenty-two subjects completed the drug regimen without surgery or radioiodine treatment.
Results
At baseline, TSI was highly correlated with TRAb (r s =0.64, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Diabetes, Uppsala University Hospital, Uppsala, Sweden.
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Förderung
- Uppsala Universitet
Zitieren
APA
Khamisi, S., Lundqvist, M., Engström, B. E., Larsson, A., Karlsson, F. A., & Ljunggren, Ö. (2023). Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy. Experimental and Clinical Endocrinology & Diabetes, 131(04), 236-241. https://doi.org/10.1055/a-2021-0596
Vancouver
Khamisi S, Lundqvist M, Engström BE, Larsson A, Karlsson FA, Ljunggren Ö. Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy. Experimental and Clinical Endocrinology & Diabetes. 2023;131(04):236-241. doi:10.1055/a-2021-0596
BibTeX
@article{Khamisi2023,
author = {Khamisi, Selwan and Lundqvist, Martin and Engström, Britt Edén and Larsson, Anders and Karlsson, F Anders and Ljunggren, Östen},
title = {Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves’ Orbitopathy},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2023},
volume = {131},
number = {04},
pages = {236--241},
doi = {10.1055/a-2021-0596}
}
EUVIMED